Objectives To determine the association of furosemide therapy with the incidence of bone fractures in children with congenital heart disease.
health insurance coverage for low-income families, individuals with chronic disabilities, blind persons, low-income pregnant women, elderly people or seniors, nondisabled children, and caretakers of dependent children. Medicaid enrollment in the state of Texas for clients <21 years of age is approximately 3 million for 2016. 12 The study was approved by the University of Texas at Austin Institutional Review Board and by the Texas Health and Human Services Commission. The following information was extracted from the Texas Medicaid database: date of birth, sex, race/ethnicity, start and end dates of health plan enrollment, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, Healthcare Common Procedure Coding System codes, service dates, quantity of the medication dispensed, the number of days of supply, National Drug Code, Generic Sequencing Number, and American Hospital Formulary Service number.
Study Design
A retrospective cohort study design was used to assess the association of furosemide use and fractures. Both inpatients and outpatients were included in the study if they were <12 years of age and had ≥1 claim with a diagnosis of CHD, cardiomyopathy, or heart failure. Many patients were diagnosed as infants; therefore, 1 year of previous use before the index date was not required, but all were required to have ≥1-year of follow-up data (ie, be enrolled and using services) past their medication index date. Patients were excluded if the first date for a diagnosis claim for CHD, cardiomyopathy, or heart failure occurred after the medication index date. In addition, if patients had any claims for diuretic prescriptions or ICD-9-cardiomyopathy codes for fractures on or before their medication index date they were also excluded from analysis. The study timeframe was described in Appendix 1 (available at www.jpeds.com).
Under the assumption that a patient used furosemide chronically, those who met study criteria were divided into 3 groups.
Furosemide-Adherent Group. The date of the first prescription for furosemide was considered the patient's medication index date. If the patient had at least 256 days of furosemide prescriptions during the first year post-index (ie, medication possession ratio [MPR] of ≥ 70%), they were categorized into the furosemide-adherent group. A wide range of cutoff adherence values for the MPR (63%-89%) have been used in previous adherence studies. 13 However, the MPR cutoff of 70% was used for this study based on the distribution of adherence in this sample (ie, natural break). A sensitivity analysis was conducted to validate the base model using the more commonly used 80% cutoff MPR.
Furosemide-Nonadherent Group. Again, the date of the first prescription for furosemide was considered the patient's medication index date. If the patient had <256 days of furosemide prescriptions during the first year postindex (ie, a MPR of <70%), they were categorized into the furosemidenonadherent group.
No Furosemide Group. If patients did not have a furosemide prescription at any time, but had another diuretic prescription, their index date was defined as the first date of this diuretic prescription fill. The other type of diuretics included potassium-sparing diuretics and thiazide diuretics. If patients did not have any prescriptions for diuretics, a random index date was generated from the list of medication fill dates for that patient within one year from the first prescription claim date. Patients with nonfurosemide diuretics or no diuretics were combined to form the no furosemide group.
Study Outcomes and Covariates
The primary outcome was the new occurrence of a bone fracture within the postindex period. To control for other factors that might be associated with the incidence of fractures, additional variables were included as covariates in the multivariate analyses. First, patients were divided into those who only had a CHD diagnosis and those that had either a cardiomyopathy and/or heart failure diagnosis in addition to a CHD diagnosis. Second, 2 diseases indicators were selected as covariates to assess comorbidity: a diagnosis of bronchopulmonary dysplasia (ICD-9-CM 770.7) and a diagnosis of low birth weight or prematurity (ICD-9-CM 764.x, 765.x). Next, clinical factors were included to adjust severity of disease: heartrelated surgery (eg, heart surgery, aortic valve repair) and use of proton pump inhibitors (PPIs; ie, omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole, and dexlansoprazole), which have also been shown to increase fracture risk. [14] [15] [16] In addition, the use of less commonly used medications-H2-antagonist, beta-blockers, and calcium or vitamin D supplementation-were added in a sensitivity analysis. These agents were identified only when their claims were found between the first date of diagnosis of CHD, cardiomyopathy, or heart failure and the first date of the occurrence of a fracture. For those who did not have any fractures in the study period, a random date within 1 year from the index date was used instead of first fracture date. In addition, other demographic factors included in the model were age at index date; sex; and race/ethnicity (white, black, Hispanic, and others [Asian, Native Hawaiian, or uncategorized race]). The detailed ICD-9-CM codes for CHD, cardiomyopathy, heart failure, and fractures used in this study are described in Appendix 2 and Appendix 3 (available at www.jpeds.com).
Statistical Analyses
Baseline characteristics and treatment variables were compared using c 2 tests for all categorical variables and ANOVA tests for all continuous variables. Matching was performed using the propensity score matching method to reduce the bias in covariates among 3 groups. Propensity scores were generated using logistic regression and the matching used a greedy algorithm, which uses the nearest available pair matching methods. 17 Covariates used for logistic regression included all covariates as described, including both demographic and clinical factors. The incidence of fracture occurrence was compared among groups using c 2 tests. To estimate the odds of a fracture in the study population, a logistic regression of the Volume 199 • August 2018 matched patients, controlling for covariates, was conducted. In addition, the log-rank test was used to compare survival distribution among the 3 groups, and a Cox proportional hazard model with a Kaplan-Meier plot (survival curve) was used to assess time to fracture controlling for covariates. All data management and statistical analyses were completed using SAS versions 9.4 (SAS Institute Inc, Cary, North Carolina) and Stata Statistical Software: Release 14 (StataCorp, College Station, Texas). P < .05 was considered statistically significant a priori.
Results
A total of 53 725 patients (furosemide-adherent, n = 466; furosemide nonadherent, n = 2810; no furosemide, n = 50 449) met the study criteria (Appendix 4; available at www.jpeds.com). The median follow-up periods were about 3 years for each of the 3 groups. Significant differences in all demographic and clinical characteristics (P < .001, except sex: P < .02; Table I ) were found between the unmatched groups at baseline. After propensity score matching, a final sample size of 3912 patients (furosemide-adherent, n = 254; furosemide nonadherent, n = 724; no furosemide, n = 2934) was created with no differences in all baseline demographics ( Table I ). The vast majority (>91%) had ≥2 claims for CHD. Few patients had any claim for nonfurosemide diuretics, such as thiazide or potassium-sparing diuretics: furosemide-adherent (3.9%, n = 10), furosemide nonadherent (1.5%, n = 11), and no furosemide group (1.7%, n = 51).
The incidence rate of a fracture was significantly higher for the furosemide-adherent group compared with both the furosemide nonadherent group and the no furosemide group for both the unmatched and matched cohorts (P < .001). Before matching the fracture rate was highest for the furosemideadherent group (9.0%), followed by the furosemide nonadherent group (5.6%), which were both higher than for patients who did not receive furosemide (3.6%). After propensity score matching, the fracture rate remained highest for the furosemide-adherent group (9.1%), followed by the furosemide-nonadherent group (7.2%), which were both higher than for patients who did not receive furosemide (5.0%). Appendix 5 and Appendix 6 (available at www.jpeds.com) show the frequencies of the site of fractures per each group for original and matched population.
In the logistic regression model, the odds of having a fracture were 87% higher for the furosemide-adherent group compared with the no furosemide group, despite controlling for covariates (OR, 1.9; 95% CI, 1.17-2.98; P = .009; Table II ). The 
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Volume 199 furosemide-nonadherent group also had a 54% higher odds of having fractures than the no furosemide group (OR, 1.5; 95% CI, 1.10-2.14; P = .01). Significant covariates for fractures were age, race/ethnicity, CHD only diagnosis, and PPI use. As each year in age increases, the odds of a fracture increased 1.2 times (OR, 1.15; 95% CI, 1.08-1.23; P < .001). Hispanic and black patients showed a reduced risk of fracture compared with white patients (Hispanic: OR, 0.6 [95% CI, 0.42-0.95; P = .03]; black: OR, 0.5 [95% CI, 0.24-0.99; P = .05]). When patients had only a CHD diagnosis, the odds of fractures were lower than patients with a comorbid diagnosis of CHD and cardiomyopathy or heart failure (OR, 0.6; 95% CI, 0.45-0.82; P = .001). The OR for PPIs users was 1.6 versus PPIs nonusers (95% CI, 1.15-2.20; P = .005). Table III shows the results of the Cox proportional hazards regression model comparing the occurrence of fractures among cohorts including a time-to-fracture component while controlling for covariates. The proportional hazards assumption was met, meaning that the hazards ratio is a constant that does not depend on time (P = .42). This model indicated that furosemide-adherent patients had a 56% (HR, 1.6; 95% CI, 1.00-2.42; P = .04) increased risk of fractures consistently over 3 years, compared with furosemide nonusers. The furosemide-nonadherent group also had an increased risk versus the no furosemide group, but this increase trended toward but did not reach statistical significance (HR, 1.37; 95% CI, 1.00-1.89; P = .05). Similar to the logistic regression, significant covariates were race/ethnicity, CHD only, and PPI use. Hispanic and black patients showed a reduced risk of fracture compared with white patients (Hispanic: OR, 0.6 [95% CI, 0.44-0.94; P = .02]; black: OR, 0.5 [95% CI, 0.25-0.98; P = .04]). Patients with only CHD had a 34% lower risk of fractures compared with patients with dual diagnoses (ie, CHD/cardiomyopathy or CHD/heart failure) (HR, 0.7; 95% CI, 0.49-0.88; P = .004). PPIs users had 47% higher risk of fracture than nonusers (HR, 1.5; 95% CI, 1.08-2.00; P = .02). The log-rank test showed that furosemide users have significantly different survival distributions compared with nonusers (c 2 = 8.17; P = .02). Furosemide-adherent patients had a shorter time to fracture as demonstrated by Kaplan-Meier analysis ( Figure) .
The 2 sensitivity analyses using results with smaller cell sizes: using a cutoff MPR of 80%, and the addition of 3 covariates-H2-antagonists, beta-blocker use, and calcium or vitamin D supplementation-showed the same direction of results as the base model (Appendixes 7-10; available at www.jpeds.com), and the regression analyses indicated a significant difference for furosemide users. For the sensitivity analyses applied to the Cox proportional hazards model, again results were in the same direction, but no longer statistically different at the alpha level of .05 (P = .08 for MPR 80% and P = .16 when 3 new covariates were added). 
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Discussion
We found that patients with CHD on chronic furosemide therapy were nearly twice as likely to have a fracture compared with patients who were not on this therapy. The role of diuretics in fracture is further supported by the increased risk of fracture in those patients who had more prescription refills for a diuretic, suggesting a dose-response type effect. Although the finding of diuretic-associated fracture is wellknown in adult patients, this result is unique in this highrisk subset of the pediatric population. 7, 18, 19 It is also unique that in our analysis, the patient population evaluated is older than previous reports, demonstrating bone mineral density defects in premature neonates and infants. [20] [21] [22] [23] [24] The use of furosemide in pediatric patients with CHD is common, and our findings may spur further investigation and potentially a higher clinical suspicion to evaluate for fractures. 25 Additionally, there were several other findings in our report which warrant discussion and evaluation from a clinical perspective.
We noted that patients with a dual diagnosis of CHD/ cardiomyopathy or CHD/heart failure were at a greater risk of fracture than those patients with only CHD. Prior investigations have noted the risk of bone fracture in infants with CHD admitted to the cardiac intensive care unit, although it is unclear as to the etiology for the fractures reported. 21 Vitamin D deficiency is known to be common in patients with CHD and cardiopulmonary bypass has been shown to decrease vitamin D levels in patients undergoing surgery for CHD. 26, 27 Additionally, patients who have undergone a single ventricle palliation with the Fontan procedure have demonstrated decreases in bone mineral density at a median of 10 years after the surgical procedure. 28 However, vitamin D has also been shown to be low in pediatric patients with heart failure and no CHD. 29 The lower levels of vitamin D could be a risk factor for fracture in this patient population. Overall, patients with CHD only were less likely to experience a fracture, which may be due to lower doses or frequency of furosemide when compared with patients with heart failure (P < .001). The presence of CHD, and the underlying genotype that give rise to this phenotype, seem to influence the risk of fracture. Given these findings, vitamin D supplementation should be considered in children with CHD on chronic loop diuretic therapy. 30 A difference in sex with regard to fracture risk was not seen, despite data suggesting that this may play a role. 31 White patients were at a greater risk of developing a fracture in comparison with Hispanic or black patients in our analysis. The racial/ethnic differences in bone mineral density and fracture risk are well-documented. 7, [31] [32] [33] [34] For example, it has been reported that blacks with osteoporosis have higher bone density scores as compared with white patients, which in turn is related to a lower incidence rate of fractures. 35 These factors should be taken into account when assessing a patient for chronic diuretic therapy.
The use of PPIs was associated with an increased risk of fracture, a finding previously reported. [36] [37] [38] Despite this risk, these agents are frequently prescribed in children with heart disease. [39] [40] [41] It is important to note that the effect of loop diuretic therapy on fracture persisted when adjusted for PPI use. Fractures may be able to be mitigated by decreased use of PPIs. [41] [42] [43] Clinicians should be cognizant of the increased risk of fracture when using PPIs in children with CHD on chronic loop diuretic therapy and tailor use accordingly.
The limitations of this report are those that are germane to large database analyses. The current analysis only allows the reporting of an association between diuretic use and fracture incidence. We believe that a causal relationship is likely, based on the clinical pharmacology of loop diuretics and the prior literature, but cannot establish causation. There is an assumption made that patients who refilled medications were actually taking those medications, which we also cannot validate. The claims database also limited the validation of sensitivity between prescribed and filled prescription because Texas Medicaid database included only filled prescription data. Claims databases do not have the granularity to assess pertinent clinical information, such as bone mineral density values, severity of heart disease, vitamin D status, calcium/vitamin D supplementation, or fracture etiology. We were unable to quantify immobility, infection, inflammation, or dietary calcium using the claims database. However, McNally et al reported that the patients who receive a standard of care did not show additional cases of hypercalcemia or hypercalciuria. 44 We would not expect that there would be a difference in over-the-counter calcium or vitamin D supplementation between the high-dose and lowdose furosemide groups, or nonusers group. The sensitivity analysis was conducted-controlling for calcium or vitamin D supplement-to reduce potential bias and showed the same direction with primary results. This study can serve as the basis for future investigations using robust clinical data. Next, this was a nonrandomized retrospective analysis; therefore, the presence of differences in baseline patient characteristics can result in bias results. Although propensity score matching and regressions were used to account for some baseline differences, there may be unmeasured variables that can introduce bias.
Next, thiazide is known to decrease renal calcium excretion and have been associated with increased bone mineral density, resulting likely decreased the risk of fractures. 45 However, in our matched population, only 10 patients who took ≥1 claim for thiazide were identified in furosemide group. Moreover, because a 1-time administration of thiazide would not be enough to decrease the chance of a fracture, the use of thiazides was not considered as a covariate. Sedative medications that may be related to fractures encompass a large number of medication classes and were considered too broad to be a useful covariate. Overall, despite the limitations associated with using claims data, the data presented are similar to the results of other investigations in adults and make a compelling case for further investigations into bone health in pediatric patients with CHD who are treated with loop diuretics. ■
Data Statement
Data will be made available on request.
Appendix II. ICD-9-CM Code for Congenital Heart Disease, Cardiomyopathy, and Heart Failure

ICD-9-CM Codes Description
Congenital heart disease 745.0 Common truncus 745. 10 Complete transposition of great vessels 745.11 Double outlet right ventricle 745. 12 Corrected transposition of great vessels 745. 19 Other transposition of great vessels 745. Congenital heart block 746.87
Malposition of heart and cardiac apex 746.89
Other specified congenital anomalies of heart 746. 9 Unspecified congenital anomaly of heart 747.0 Patent ductus arteriosus 747. 10 Coarctation of aorta (preductal) (postductal) 747. 11 Interruption of aortic arch 747. 20 Anomaly of aorta, unspecified 747. 21 Anomalies of aortic arch 747. 22 Atresia and stenosis of aorta 747. 29 Other anomalies of aorta 747. 31 Pulmonary artery coarctation and atresia 747. 32 Pulmonary arteriovenous malformation 747. 39 Other anomalies of pulmonary artery and pulmonary circulation 747. 40 Anomaly of great veins, unspecified 747. 41 Total anomalous pulmonary venous connection 747. 42 Partial anomalous pulmonary venous connection 747. 49 Other anomalies of great veins V15. 1 Personal history of surgery to heart and great vessels, presenting hazards to health Cardiomyopathy 425.0 Endomyocardial fibrosis 425.11
Hypertrophic obstructive cardiomyopathy 425. 18 Other hypertrophic cardiomyopathy 425. 2 Obscure cardiomyopathy of Africa 425. 3 Endocardial fibroelastosis 425. 4 Other primary cardiomyopathies 425. 5 Alcoholic cardiomyopathy 425. 7 Nutritional and metabolic cardiomyopathy 425. 8 Cardiomyopathy in other diseases classified elsewhere 425. 9 Secondary cardiomyopathy, unspecified Heart failure 428.0 Congestive heart failure, unspecified 428.1
Left heart failure 428. 20 Systolic heart failure, unspecified 428. 21 Acute systolic heart failure 428. 22 Chronic systolic heart failure 428. 23 Acute on chronic systolic heart failure 428. 30 Diastolic heart failure, unspecified 428. 31 Acute diastolic heart failure 428. 32 Chronic diastolic heart failure 428. 33 Acute on chronic diastolic heart failure 428. 40 Combined systolic and diastolic heart failure, unspecified 428. 41 Acute combined systolic and diastolic heart failure 428. 42 Chronic combined systolic and diastolic heart failure 428. 43 Acute on chronic combined systolic and diastolic heart failure 428. 9 Heart failure, unspecified 
